VRNA Verona Pharma plc

6.1
-0.04  -1%
Previous Close 6.14
Open 6.11
Price To Book 0.96
Market Cap 80311557
Shares 13,165,829
Volume 2,258
Short Ratio
Av. Daily Volume 13,072

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
Phase 2 trial did not meet primary endpoint - January 14, 2019.
RPL554
COPD
Phase 2 interim positive data released March 4, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD

Latest News

  1. PDMR Dealing
  2. Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
  3. Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
  4. Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
  5. Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
  6. Verona Pharma to Present at Upcoming Investor Conferences
  7. Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?
  8. Verona Pharma Enters Oversold Territory
  9. Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
  10. Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
  11. Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
  12. Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554
  13. Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
  14. Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
  15. Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
  16. Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update